{"filings":[{"id":97934,"accession_number":"0001493152-26-018160","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Provectus to hold 2026 annual meeting at planned new headquarters, Perkins Place in Knoxville","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting set for June 18, 2026 at 4:00 p.m. ET at Perkins Place, 525 Portland Street, Knoxville.","Company plans to relocate headquarters to Perkins Place in 2026; first stockholder gathering at new location.","Perkins Place is a 22,941 sq ft renovated historic school building on 3.23 acres with expansion potential.","Chairman & CEO Ed Pershing reacquired property in fall 2025 via partnership with East Tennessee Foundation.","Relocation cited to manage costs and enable future facility development for research, operations, or logistics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113144,"accession_number":"0001493152-26-004730","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Provectus extends automatic conversion date for Series D and D-1 preferred stock to Dec 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Automatic conversion date for Series D and D-1 preferred stock extended from June 20, 2026 to December 31, 2028.","Amendments apply to Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, both par value $0.001.","Board of directors and a special committee of independent directors approved the amendments.","No changes to conversion terms other than the extension of the conversion date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164417,"accession_number":"0001641172-25-015695","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Provectus shareholders approve reverse stock split authorization and elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all four director nominees: Bailey, Lacey, Pershing, Rodrigues, with >200M votes for each.","Advisory say-on-pay approved: 195.7M for, 15.1M against, 0.4M abstentions; 138.8M broker non-votes.","Ratified CBIZ CPAs P.C. as independent auditor for 2025: 337.9M for, 6.2M against, 5.8M abstentions.","Authorized board to implement reverse stock split at ratio between 1:10 and 1:50; 326.8M for, 18.2M against.","Authorized reduction in authorized shares by same reverse split ratio; 330.5M for, 16.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164416,"accession_number":"0001641172-25-015520","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Provectus provides broad business update at annual meeting; no specific results disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company presented on clinical development, regulatory, discovery, manufacturing, IP, and corporate development.","Presentation slides furnished as exhibit 99.1 to the 8-K filing.","No financial results, clinical data, or guidance changes were included in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164415,"accession_number":"0001641172-25-004995","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Provectus BioPharma appoints CBIZ as new auditor following Marcum acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 15, 2025, due to its acquisition by CBIZ.","Audit Committee approved engagement of CBIZ CPAs P.C. as successor auditor on the same date.","No disagreements or reportable events occurred with Marcum during 2024, 2023, or through resignation date.","Audit reports for fiscal years 2024 and 2023 were unmodified and not qualified.","Marcum letter agreeing with statements filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182174,"accession_number":"0001493152-25-003193","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Provectus Biopharma approves up to $10M convertible loan financing for drug development","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Board approved 2025 Term Sheet to arrange up to $10M unsecured convertible loan in tranches.","Loan bears 8% annual interest; principal and interest convertible into Series D-1 Preferred at $2.8620 per share, each convertible into 10 common shares.","Proceeds to fund drug discovery and development program and general & administrative expenses.","Company closed 2024 Financing with $1M in convertible promissory notes received as of January 15, 2025.","Issuance of notes exempt from registration under Section 4(a)(2) or Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198815,"accession_number":"0001493152-24-052029","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Provectus assigns exclusive ophthalmic license to majority-owned subsidiary VisiRose","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Assigns exclusive license with University of Miami for photodynamic antimicrobial therapy in ophthalmology to VisiRose, effective Dec 9, 2024.","VisiRose is a majority-owned subsidiary focused on developing rose bengal sodium for ophthalmology diseases and disorders.","University of Miami approved assignment and novation, releasing Provectus from future obligations under the license.","Provectus grants VisiRose a non-exclusive, worldwide, royalty-free license to Licensee Background IP as needed.","Agreement reflects Provectus's strategy to separate ophthalmic assets into a dedicated subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198814,"accession_number":"0001493152-24-049571","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Provectus launches VisiRose subsidiary to develop RB PDAT for eye infections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VisiRose formed as Delaware subsidiary to commercialize rose bengal sodium for ophthalmology, targeting infectious keratitis.","Seed round term sheet (non-binding) for up to $3M in three tranches at valuations tied to Series A; 5,278 Class B shares issued.","University of Miami (Bascom Palmer) receives minority equity; 5% ownership until $2M qualified investment.","Initial directors: Webster Bailey, Jack Lacey, Ed Pershing (Chair). Officers: Dominic Rodrigues (Acting CEO), Heather Raines (Acting CFO).","RB PDAT tested in >500 patients globally; targeting $60B ophthalmic market with broad-spectrum antimicrobial therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198813,"accession_number":"0001493152-24-048734","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Provectus grants ~49.5M stock options to CEO, President, CFO, CTO, directors; CFO salary raised to $200K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Ed Pershing receives 25,470,215 options (grant date value $3,081,896) at $0.2862 exercise price.","President Dominic Rodrigues receives 16,146,600 options ($1,953,739); CFO Heather Raines receives 4,197,890 options ($507,945).","CFO base salary increased from $125,000 to $200,000 effective Dec 1, 2024; new employment agreement includes change-in-control provisions.","Options vest in three equal annual installments for officers; independent directors’ options vest immediately.","All option grants approved by Board on Nov 18, finalized Dec 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198812,"accession_number":"0001493152-24-045353","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Provectus references Q4 2024 investor update; no specific details in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing announces Fourth Quarter 2024 Investor Update presentation slides as Exhibit 99.1.","Presentation covers clinical, non-clinical, regulatory, manufacturing, and corporate development updates.","The exhibit content was not provided in this filing, so no concrete updates are available.","No financial or operational data disclosed; confidence in material news is low."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214845,"accession_number":"0001493152-24-033053","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Provectus converts $2.13M in director fees to Series D-1 Preferred shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted $2,131,838.75 in accrued directors’ fees into 744,878 shares of Series D-1 Preferred at $2.862 per share.","Preferred shares are convertible into 7,448,780 shares of common stock.","Issuance covers fees owed through September 30, 2024; not under 2024 Equity Compensation Plan.","Board approved on August 14, 2024; fees had been accruing since April 2017."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214844,"accession_number":"0001493152-24-028157","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Provectus announces up to $10M convertible loan financing at 8% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Board approved term sheet for up to $10M unsecured convertible loan (2024 Financing) from multiple investors.","Loan bears 8% annual interest, matures in 12 months, convertible into Series D-1 Preferred at $2.8620/share.","Series D-1 Preferred convertible into 10 shares of common stock per preferred share.","Proceeds will fund drug discovery and development programs and G&A expenses.","Also closed previously reported 2022 Financing totaling $4,865,500 as of July 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234016,"accession_number":"0001493152-24-025080","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Provectus redeems 11.4M Series D shares for 1.14M Series D-1 shares; authorized share counts amended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VP and President Dominic Rodrigues forfeits 11,416,262 Series D Preferred shares for 1,141,626 Series D-1 shares.","Series D authorized shares reduced from 12,374,000 to 957,100; Series D-1 increased from 11,241,000 to 23,042,900.","Company states new Series D-1 shares are economically equivalent to the forfeited Series D shares.","Amendments to certificates of designation filed with Delaware Secretary of State on June 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234015,"accession_number":"0001493152-24-024661","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Provectus shareholders approve reverse stock split authorization and other proposals at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six proposals passed at June 20, 2024 annual meeting; directors elected with >96% votes cast.","Reverse stock split (1:10 to 1:50) authorized with 302.9M for (92.4%); authorized share reduction also approved.","Advisory vote on executive compensation passed with 202.8M for (96.6%); broker non-votes 115.0M.","Marcum LLP ratified as auditor for 2024 with 325.7M for (99.6%); no broker non-votes.","2024 Equity Compensation Plan approved with 198.3M for (94.0%); broker non-votes 115.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234014,"accession_number":"0001493152-24-024449","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Provectus presents annual meeting update covering R&D and corporate activities; no specific results disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Update covers clinical development, regulatory, drug discovery, manufacturing, IP, and business development.","No financial or clinical data points released in the filing.","Presentation slides furnished as Exhibit 99.1 but not reproduced in the text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.12,"calibrated_materiality_score":0.12,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234013,"accession_number":"0001493152-24-014848","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Provectus appoints Pershing as CEO and Rodrigues as President effective April 16","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ed Pershing appointed CEO effective April 16; will continue as Board Chairman; salary $240,000/year.","Dominic Rodrigues appointed President effective April 16; will continue as Vice Chairman; salary $240,000/year.","Both executives have employment agreements with change-in-control severance provisions.","Rodrigues' prior independent contractor agreement (March 2024) terminated; he had served as chief operating consultant.","Press release outlines 2024 focus: pancreatic cancer clinical program, capital raising at fair valuation, and enhanced investor outreach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251974,"accession_number":"0001493152-24-011443","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Provectus licenses University of Miami's rose bengal PDAT for eye infections; will form spinout","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license for photodynamic antimicrobial therapy (PDAT) using rose bengal sodium to treat bacterial, fungal, and acanthamoeba keratitis.","Upfront fee of $10k; 10% royalty on net sales; annual maintenance fees of $1k (years 1-4) then $10k; development milestones up to $55k.","Company to form a majority-owned NewCo within one year; University gets 5% equity and up to 30% of sublicense income depending on clinical phase.","Technology supported by two international randomized clinical trials (NCT05110001, NCT06271772) for acanthamoeba/fungal and bacterial keratitis.","Provectus will supply pharmaceutical-grade rose bengal sodium to NewCo exclusively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251973,"accession_number":"0001493152-24-011327","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Provectus Biopharmaceuticals Names Dominic Rodrigues Principal Executive Officer; Bruce Horowitz Resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruce Horowitz resigned as COO and Director on March 25, 2024, and entered a termination agreement with a total payment of up to $750,000.","The termination agreement includes an initial $250,000 payment and a second payment of $258,000 if paid before June 30, 2024, otherwise $500,000.","Dominic Rodrigues was appointed as chief operations consultant and principal executive officer with a monthly fee of $20,000.","The company agreed to continue D&O insurance for Horowitz for two years and Horowitz agreed to a five-year standstill.","The termination agreement includes mutual releases, confidentiality reaffirmation, and non-disparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251972,"accession_number":"0001493152-24-007506","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Provectus holds conference call and furnishes slide deck; no specific details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company hosted conference call on Feb 22, 2024 at 3:00 PM EST to provide updates.","Slide presentation furnished as Exhibit 99.1, but its content is not included in this filing.","No financial figures, guidance, or material events disclosed in the body of the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251971,"accession_number":"0001493152-24-006815","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","ticker":"PVCT","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Provectus Biopharmaceuticals to host conference call on Feb 22, 2024 for company updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Conference call scheduled for February 22, 2024 at 3:00 p.m. EST to discuss company updates.","Dial-in: 1-800-319-4610 (US) or 1-604-638-5340 (international); advance registration available.","No financial results or specific material events disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":25805183.498461537,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}